United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $259.70, for a total value of $934,920.00. Following the sale, the chief executive officer now directly owns 130 shares of the company's stock, valued at $33,761. The transaction was disclosed in a document filed with the SEC, which is available through this link.
United Therapeutics Stock Performance
UTHR opened at $266.22 on Wednesday. The firm has a market capitalization of $11.81 billion, a P/E ratio of 12.59 and a beta of 0.54. The stock's 50 day moving average price is $238.38 and its two-hundred day moving average price is $229.88. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $266.65.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company's revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the firm posted $4.86 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current year.
Institutional Trading of United Therapeutics
Biden Nomination CANCELED?
From The Freeport Society | Ad
The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.”
Why is he all BUT guaranteed the Democratic nomination, in their words?
I believe I have the terrifying answer right here.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Rise Advisors LLC acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $32,000. GAMMA Investing LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 117 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $91,000. Finally, Janiczek Wealth Management LLC grew its holdings in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company's stock worth $111,000 after purchasing an additional 84 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on UTHR. Wedbush reaffirmed an "outperform" rating and set a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group raised their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a "neutral" rating in a research note on Friday, May 3rd. Oppenheimer raised their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research note on Thursday, May 2nd. Wells Fargo & Company raised their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research note on Thursday, March 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $308.78.
Read Our Latest Research Report on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
